Cancer cell sensitivity to bortezomib is associated with survivin expression and p53 status but not cancer cell types

Journal of Experimental and Clinical Cancer Research

Volumn 29, Issue 1, 2010, Pages

  Ling, Xiang ^a   Calinski, Diane ^a   Chanan Khan, Asher A ^a   Zhou, Muxiang ^b   Li, Fengzhi ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; BORTEZOMIB; CASPASE; MESSENGER RNA; PROTEIN P53; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; SURVIVIN; BIRC5 PROTEIN, HUMAN; BORONIC ACID DERIVATIVE; MICROTUBULE ASSOCIATED PROTEIN; PYRAZINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL LINE; CELL TYPE; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG SENSITIVITY; ENZYME ACTIVITY; FLOW CYTOMETRY; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; MUTANT; PRIORITY JOURNAL; PROTEIN INDUCTION; RECEPTOR DOWN REGULATION; RNA INTERFERENCE; WESTERN BLOTTING; WILD TYPE; CELL STRAIN HCT116; DRUG EFFECT; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOPLASM; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

APOPTOSIS; BORONIC ACIDS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENES, P53; HCT116 CELLS; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASMS; PYRAZINES; RNA, SMALL INTERFERING;

EID: 77449158252     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-29-8     Document Type: Article

References (50)

1. Antitumor effects and drug interactions of the proteasome inhibitor bortezomib (PS341) in gastric cancer cells. T Fujita H Doihara K Washio H Ino M Murakami M Naito N Shimizu, Anticancer Drugs 2007 18 677 686 10.1097/CAD.0b013e32808bf9d8 17762396
2. A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer. H Mackay D Hedley P Major C Townsley M Mackenzie M Vincent P Degendorfer MS Tsao T Nicklee D Birle, et al. Clin Cancer Res 2005 11 5526 5533 10.1158/1078-0432.CCR-05-0081 16061869
3. Bortezomib with or without irinotecan in relapsed or refractory colorectal cancer: results from a randomized phase II study. PS Kozuch CM Rocha-Lima T Dragovich H Hochster BH O'Neil OT Atiq JM Pipas DP Ryan HJ Lenz, J Clin Oncol 2008 26 2320 2326 10.1200/JCO.2007.14.0152 18467723
4. Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2-positive breast cancer cells in a synergistic manner. F Cardoso V Durbecq JF Laes B Badran L Lagneaux F Bex C Desmedt K Willard-Gallo JS Ross A Burny, et al. Mol Cancer Ther 2006 5 3042 3051 10.1158/1535-7163.MCT-06- 0104 17148762
5. Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells. J Codony-Servat MA Tapia M Bosch C Oliva J Domingo-Domenech B Mellado M Rolfe JS Ross P Gascon A Rovira J Albanell, Mol Cancer Ther 2006 5 665 675 10.1158/1535-7163.MCT-05-0147 16546981
6. Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits. CH Yang AM Gonzalez-Angulo JM Reuben DJ Booser L Pusztai S Krishnamurthy D Esseltine J Stec KR Broglio R Islam, et al. Ann Oncol 2006 17 813 817 10.1093/annonc/mdj131 16403809
7. A phase II study of single agent bortezomib in patients with metastatic breast cancer: a single institution experience. RH Engel JA Brown JH Von Roenn RM O'Regan R Bergan S Badve A Rademaker WJ Gradishar, Cancer Invest 2007 25 733 737 10.1080/07357900701506573 17952740
8. Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study. A Awada J Albanell PA Canney LY Dirix T Gil F Cardoso P Gascon MJ Piccart J Baselga, Br J Cancer 2008 98 1500 1507 10.1038/sj.bjc. 6604347 18454159
9. A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines. P Schmid D Kuhnhardt P Kiewe S Lehenbauer-Dehm W Schippinger R Greil W Lange J Preiss N Niederle P Brossart, et al. Ann Oncol 2008 19 871 876 10.1093/annonc/mdm569 18209010
10. Bortezomib as a potential treatment for prostate cancer. CN Papandreou CJ Logothetis, Cancer Res 2004 64 5036 5043 10.1158/0008-5472.CAN-03-2707 15289299
11. Phase I/II trial of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer. N Price R Dreicer, Clin Prostate Cancer 2004 3 141 143 15636679 (Pubitemid 40051704)
12. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. CN Papandreou DD Daliani D Nix H Yang T Madden X Wang CS Pien RE Millikan SM Tu L Pagliaro, et al. J Clin Oncol 2004 22 2108 2121 10.1200/JCO.2004.02.106 15169797
13. A phase II trial of bortezomib and prednisone for castration resistant metastatic prostate cancer. MJ Morris WK Kelly S Slovin C Ryan C Eicher G Heller HI Scher, J Urol 2007 178 2378 2383 10.1016/j.juro.2007.08.015 17936848
14. Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer. R Dreicer D Petrylak D Agus I Webb B Roth, Clin Cancer Res 2007 13 1208 1215 10.1158/1078-0432.CCR-06-2046 17317831 (Pubitemid 46424062)
15. Activity of bortezomib in advanced non-small-cell lung cancer. KG Reddy, Clin Lung Cancer 2004 6 141 142 15555213
16. Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. MP Fanucchi FV Fossella R Belt R Natale P Fidias DP Carbone R Govindan LE Raez F Robert M Ribeiro, et al. J Clin Oncol 2006 24 5025 5033 10.1200/JCO.2006.06.1853 17075122
17. Randomized phase II trial of docetaxel plus cetuximab or docetaxel plus bortezomib in patients with advanced non-small-cell lung cancer and a performance status of 2: CALGB 30402. R Lilenbaum X Wang L Gu J Kirshner K Lerro E Vokes, J Clin Oncol 2009 27 4487 4491 10.1200/JCO.2009.22.7066 19704058
18. Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade((R))) in chemotherapy-naive patients with advanced stage non-small cell lung cancer (NSCLC). T Li L Ho B Piperdi T Elrafei FJ Camacho JR Rigas R Perez-Soler R Gucalp, Lung Cancer 2009
19. Control of apoptosis and mitotic spindle checkpoint by survivin. F Li G Ambrosini EY Chu J Plescia S Tognin PC Marchisio DC Altieri, Nature 1998 396 580 584 10.1038/25141 9859993
20. Survivin in apoptosis control and cell cycle regulation in cancer. DC Altieri, Prog Cell Cycle Res 2003 5 447 452 14593739
21. Survivin Study: What is the next wave? F Li, J Cell Physiol 2003 197 8 29 10.1002/jcp.10327 12942537
22. Survivin Study: An update of "What is the next wave?". F Li X Ling, J Cell Physiol 2006 208 476 486 10.1002/jcp.20634 16557517
23. Targeting survivin in cancer therapy. M Pennati M Folini N Zaffaroni, Expert Opin Ther Targets 2008 12 463 476 10.1517/14728222.12.4.463 18348682
24. The case for survivin as a regulator of microtubule dynamics and cell-death decisions. DC Altieri, Curr Opin Cell Biol 2006 18 609 615 10.1016/j.ceb.2006.08.015 16934447
25. Survivin: a protein with dual roles in mitosis and apoptosis. SP Wheatley IA McNeish, Int Rev Cytol 2005 247 35 88 10.1016/S0074-7696(05)47002-3 16344111
26. Transcriptional and post-transcriptional controls of survivin in cancer cells: novel approaches for cancer treatment. M Zhang J Yang F Li, J Exp Clin Cancer Res 2006 25 391 402 17167980
27. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. A Mirza M McGuirk TN Hockenberry Q Wu H Ashar S Black SF Wen L Wang P Kirschmeier WR Bishop, et al. Oncogene 2002 21 2613 2622 10.1038/sj.onc.1205353 11965534
28. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. WH Hoffman S Biade JT Zilfou J Chen M Murphy, J Biol Chem 2002 277 3247 3257 10.1074/jbc.M106643200 11714700
29. DNA Damage Induces a Novel p53-Survivin Signaling Pathway Regulating Cell Cycle and Apoptosis in Acute Lymphoblastic Leukemia Cells. M Zhou L Gu F Li Y Zhu WG Woods HW Findley, J Pharmacol Exp Ther 2002 303 124 131 10.1124/jpet.102.037192 12235242
30. Estrogen receptor alpha inhibits p53-mediated transcriptional repression: implications for the regulation of apoptosis. A Sayeed SD Konduri W Liu S Bansal F Li GM Das, Cancer Res 2007 67 7746 7755 10.1158/0008-5472.CAN-06-3724 17699779
31. Sensitization of DNA damage-induced apoptosis by the proteasome inhibitor PS-341 is p53 dependent and involves target proteins 14-3-3sigma and survivin. SA Vaziri J Hill K Chikamori DR Grabowski N Takigawa M Chawla-Sarkar LR Rybicki AV Gudkov T Mekhail RM Bukowski, et al. Mol Cancer Ther 2005 4 1880 1890 10.1158/1535-7163.MCT-05-0222 16373703
32. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma. GJ Gordon M Mani G Maulik L Mukhopadhyay BY Yeap HL Kindler R Salgia DJ Sugarbaker R Bueno, Cancer Chemother Pharmacol 2007 61 4 549 58 10.1007/s00280-007-0500-1 17522864
33. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells. X Liu P Yue S Chen L Hu S Lonial FR Khuri SY Sun, Cancer Res 2007 67 4981 4988 10.1158/0008-5472.CAN-06-4274 17510429
34. Assessment of Apoptosis-Inducing Effects of Docetaxel Combined with the Proteasome Inhibitor PS-341 in Human Lung Cancer Cells. CS Jung Z Zhou FR Khuri SY Sun, Cancer Biol Ther 2007 6 5 749 54 17387269
35. Silencing of antiapoptotic survivin gene by multiple approaches of RNA interference technology. X Ling F Li, BioTechniques 2004 36 450 454 456-460 15038160
36. Forced Expression of Survivin-2B Abrogates Mitotic Cells and Induces Mitochondria-dependent Apoptosis by Blockade of Tubulin Polymerization and Modulation of Bcl-2, Bax, and Survivin. X Ling Q Cheng JD Black F Li, J Biol Chem 2007 282 27204 27214 10.1074/jbc.M705161200 17656368
37. Enhancing effectiveness of the MDR-sensitive compound T138067 using advanced treatment with negative modulators of the drug-resistant protein survivin. X Ling X He P Apontes F Cao RG Azrak F Li, Am J Transl Res 2009 1 393 405 19956451
38. Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenstroms Macroglobulinemia. JP Laubach CS Mitsiades AM Roccaro IM Ghobrial KC Anderson PG Richardson, Leuk Lymphoma 2009 50 694 702 10.1080/10428190902866732 19452315
39. Bortezomib: a review of its use in patients with multiple myeloma. MP Curran K McKeage, Drugs 2009 69 859 888 10.2165/00003495-200969070-00006 19441872
40. The proteasome inhibitor bortezomib stabilizes a novel active form of p53 in human LNCaP-Pro5 prostate cancer cells. SA Williams DJ McConkey, Cancer Res 2003 63 7338 7344 14612532
41. Generation of a novel transgenic mouse model for bioluminescent monitoring of survivin gene activity in vivo at various pathophysiological processes: Survivin expression overlaps with stem cell markers. F Li Q Cheng X Ling A Stablewski L Tang BA Foster CS Johnson YM Rustum CW Porter, Am J Pathol 2010
42. Every single cell clones from cancer cell lines growing tumors in vivo may not invalidate the cancer stem cell concept. F Li, Mol Cells 2009 27 491 492 10.1007/s10059-009-0056-5 19390831
43. Induction of survivin expression by taxol (paclitaxel) is an early event which is independent on taxol-mediated G2/M arrest. X Ling RJ Bernacki MG Brattain F Li, J Biol Chem 2004 279 15196 15203 10.1074/jbc.M310947200 14722122
44. Bortezomib, paclitaxel, and carboplatin as a first-line regimen for patients with metastatic esophageal, gastric, and gastroesophageal cancer: phase II results from the North Central Cancer Treatment Group (N044B). A Jatoi SR Dakhil NR Foster C Ma KM Rowland Jr DF Moore Jr AJ Jaslowski SP Thomas MD Hauge PJ Flynn, et al. J Thorac Oncol 2008 3 516 520 10.1097/JTO.0b013e31816de276 18449005
45. [Expression of survivin and NF-kappaB in peripheral T-cell lymphoma and its significance.]. H Chang Y Gao JY Zhang F Shi YZ Chen, Zhongguo Shi Yan Xue Ye Xue Za Zhi 2008 16 1079 1081 18928599
46. Survivin associates with cell proliferation in renal cancer cells: regulation of survivin expression by insulin-like growth factor-1, interferon-gamma and a novel NF-kappaB inhibitor. A Sato M Oya K Ito R Mizuno Y Horiguchi K Umezawa M Hayakawa M Murai, Int J Oncol 2006 28 841 846 16525632
47. Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma. DT Yang KH Young BS Kahl S Markovina S Miyamoto, Mol Cancer 2008 7 40 10.1186/1476-4598-7-40 18489772
48. Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL. Q Liu S Hilsenbeck Y Gazitt, Blood 2003 101 4078 4087 10.1182/blood-2002-10-3231 12531793
49. Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib. MG Ooi PJ Hayden V Kotoula DW McMillin E Charalambous E Daskalaki NS Raje NC Munshi D Chauhan T Hideshima, et al. Clin Cancer Res 2009 15 7153 7160 10.1158/1078-0432.CCR-09-1071 19934289
50. Reversal of p53 epigenetic silencing in multiple myeloma permits apoptosis by a p53 activator. EM Hurt SB Thomas B Peng WL Farrar, Cancer Biol Ther 2006 5 1154 1160 10.1158/1535-7163.MCT-05-0446 16855375